Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study | Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An Observational Cohort Study | 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection | Increasing Ventilation Reduces Sars-Cov-2 Airborne Transmission In Schools | Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference
Virological characteristics of the SARS-CoV-2 XBB variant | SARS-CoV-2 infection and persistence in the human body | Long-term cardiovascular outcomes of COVID-19 | Heart-disease risk soars | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants | Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines |
Time to negative PCR conversion among high-risk patients | The Fc-effector function of COVID-19 convalescent plasma | Infectiousness of SARS-CoV-2 breakthrough infections and reinfections
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron | Structural brain changes in post-acute COVID-19 patients | Persistent post–COVID-19 smell loss | Persistent symptoms and sequelae after SARS-CoV-2 infection | VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System | Molnupiravir plus usual care versus usual care alone as early treatment for adults | Higher dose corticosteroids in hospitalized COVID-19 patients | FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 | Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine | Canine real-time detection of SARS-CoV-2 infections | Clinical Validation of a Novel T-Cell Receptor | Modelling the adjustment of COVID-19 response | Two masks can be worse than one: N95 respirator failure caused by an overlying face mask | Airflow Patterns in Double-Occupancy Patient Rooms | The epidemiology of long COVID in US adults
Immunological dysfunction persists for 8 months |
Clinical Features and Burden of Post-Acute Sequelae of SARS-CoV-2 Infection |
Demonstration of stable clusters of symptoms | Longitudinal Analysis of T cells in COVID-19 |
Reconsideration of anti-nucleocapsid IgG antibody | Early Estimates of Bivalent mRNA Vaccine |
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
Hospitalization | Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations |
COVID-19 Convalescent Plasma Outpatient Therapy | Bacterial Co-infection and Empirical Antibiotic Therapy in Patients |
Similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples |
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics | The WHO estimates of excess mortality associated with the COVID-19 pandemic |
Impact of SARS-CoV-2 variants on inpatient clinical outcome | Association of Time to Surgery After COVID-19 Infection
Progress Toward Poliomyelitis Eradication ― Afghanistan | Moderna Received FDA Emergency Use Authorization For Their Omicron-Targeting Bivalent Covid-19 Booster Vaccine In Children | Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons | Authorized Updated (Bivalent) COVID-19 Vaccines for Children | Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster | Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir | The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions | Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters
SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 | Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes | Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals
| Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants | Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022 | Triage of patients with Ebola virus disease
Is the risk of still and preterm birth affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy? | Effectiveness of Influenza Vaccination of Pregnant Women for Prevention of Maternal and Early Infant Influenza-Associated Hospitalizations in South Africa | A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic® induce durable B cell memory responses comparable to replicating smallpox vaccines | Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
Impact of community masking on COVID-19 | Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks | What is the place in therapy for nirmatrelvir/ritonavir? | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection or Vaccination in Pregnancy | Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations | Acute and postacute sequelae associated with SARS-CoV-2 reinfection
Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 | Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection | Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution | Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review | Protection against Omicron from Vaccination and Previous Infection in a Prison System | Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.
English 
Spanish